Webinar: Re­cord­ing avail­able [BE/BA News]

posted by Helmut Homepage – Vienna, Austria, 2023-04-01 12:38 (775 d 15:16 ago) – Posting: # 23520
Views: 6,834

Hi Achievwin & all,

❝ Wishful thinking: I hope they give clear direction (kill once for all) - the annoying center/group effect portion for BE studies conducted in one country and in homogenous population.

❝ ❝ FDA is organizing a webinar: A Deep Dive: FDA Draft Guidance on Statistical Approaches to Establishing Bioequivalence

Yesterday the recording was posted. You need some stamina watching it. 🥱 😴
The presenters essentially read out what’s on their slides and didn’t provide any background information whatsoever. Since the slides were available for download before, I prepared comments/questions and tried to make them short and as concise as possible.Interestingly, none of my questions were selected by the moderator. After I posted the second, I received a message “Please post your question only once.” Heck, it was a different one. One which was selected:

How is a Highly Variable Drug defined and is this information available on and within the RLD labeling?

Oh dear, what a waste of time!

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,671 registered users;
36 visitors (0 registered, 36 guests [including 26 identified bots]).
Forum time: 03:55 CEST (Europe/Vienna)

A statistical analysis, properly conducted, is a delicate dissection of
uncertainties, a surgery of suppositions.    Micheal J. Moroney

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5